Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Amelia D’Alessio"'
Autor:
Amelia D'Alessio, Antonella De Luca, Nicola Normanno, Marianeve Carotenuto, Marianna Gallo, Daniela Frezzetti, Monica R. Maiello
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 14:891-900
Cyclin-dependent kinases (CDKs) 4 and 6 regulate the transition from G0/G1-phase to S-phase of the cell cycle and have been identified as key drivers of proliferation in hormone receptor (HR)-positive breast cancer. The CDK4/6 inhibitor palbociclib i
Publikováno v:
PLoS ONE, Vol 3, Iss 2, p e1643 (2008)
Understanding the interplay between intracellular signals initiated by multiple receptor tyrosine kinases (RTKs) to give the final cell phenotype is a major pharmacological challenge. Retinoic acid (RA)-treatment of neuroblastoma (NB) cells implicate
Externí odkaz:
https://doaj.org/article/8943afaa34394b2c840f364233f01362
Autor:
Daniela Frezzetti, Nicola Normanno, Antonella De Luca, Monica R. Maiello, Cristin Roma, Amelia D'Alessio, Simona Bevilacqua, Marianna Gallo
Publikováno v:
Journal of Cellular Physiology. 231:1514-1521
Vascular endothelial growth factor A (VEGFA) is one of the main mediators of angiogenesis in non-small cell lung cancer (NSCLC). Recently, it has been described an autocrine feed-forward loop in NSCLC cells in which tumor-derived VEGFA promoted the s
Autor:
Amelia D'Alessio, Simona Bevilacqua, Monica R. Maiello, Marianna Gallo, Antonella De Luca, Nicola Normanno
Publikováno v:
Journal of Cellular Biochemistry. 116:2778-2785
Although evidence suggests that the RAF/MEK/ERK pathway plays an important role in triple negative breast cancer (TNBC), resistance to MEK inhibitors has been observed in TNBC cells. Different mechanisms have been hypothesized to be involved in this
Autor:
Marianna Gallo, Amelia D'Alessio, Monica R. Maiello, Antonella De Luca, Daniela Frezzetti, Nicola Normanno, Claudia Esposito, Nicoletta Chicchinelli
Publikováno v:
Expert opinion on therapeutic targets. 21(10)
Introduction The vascular endothelial growth factor A (VEGF) is the main mediator of angiogenesis. In addition, VEGF contributes to cancer growth and metastasis directly targeting tumor cells. VEGF overexpression and/or high VEGF serum levels have be
Autor:
Marianna Gallo, Nicoletta Chicchinelli, Maria Carmela Piccirillo, Nicola Normanno, Gaetano Rocco, Amelia D'Alessio, Antonella De Luca, Claudia Esposito, Gerardo Botti, Laura Forgione, Monica R. Maiello, Alessandro Morabito
Several different studies have addressed the role of the circulating tumor cells (CTC) in non-small-cell lung cancer (NSCLC). In particular, the potential of CTC analysis in the early diagnosis of NSCLC and in the prediction of the outcome of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c418005da3eec65d79360e3c3555bbb2
https://europepmc.org/articles/PMC5583074/
https://europepmc.org/articles/PMC5583074/
Autor:
Simona Bevilacqua, Marianna Gallo, Amelia D'Alessio, Francesco Perrone, Antonella De Luca, Monica R. Maiello, Nicola Normanno, Daniela Frezzetti, Alessandro Morabito
Publikováno v:
Expert Opinion on Investigational Drugs. 23:1295-1303
The VEGF A /VEGF receptor (VEGFR) network actively contributes to breast cancer pathogenesis and progression, playing a pivotal role in promoting tumour-associated angiogenesis. Vandetanib is a multitargeted tyrosine kinase inhibitor that selectively
Autor:
Claudia Esposito, Antonella De Luca, Rossella De Cecio, Amelia D'Alessio, Nicoletta Chicchinelli, Alessia Iannaccone, Monica R. Maiello, Nicola Normanno
Publikováno v:
Expert opinion on therapeutic targets. 21(2)
The presence of activating mutations of the epidermal growth factor receptor (EGFR) is predictive of response to first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with advanced non-small-cell lung cancer (NSCLC). However, pat
Publikováno v:
Expert Opinion on Therapeutic Targets. 16:S17-S27
The RAS/RAF/MAP kinase-ERK kinase (MEK)/extracellular-signal-regulated kinase (ERK) (MAPK) and the PI3K/AKT/mammalian target of rapamycin (mTOR) (PI3K) pathways are frequently deregulated in human cancer as a result of genetic alterations in their co
Autor:
Amelia D'Alessio, Ann M. Bode, Antonella De Luca, Ronald A. Lubet, Feng Zhu, Marna E. Ericson, Zigang Dong, Jixia Li, Clinton J. Grubbs, Nicola Normanno
Publikováno v:
Molecular Carcinogenesis. 52:134-143
Lapatinib, an oral, small-molecule, reversible inhibitor of both EGFR and HER2, is highly active in HER2 positive breast cancer as a single agent and in combination with other therapeutics. However, resistance against lapatinib is an unresolved probl